Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Receivables - Other: 2010-2024

Historic Expense - Property Taxes and Insurance for OptimizeRx (OPRX) over the last 2 years, with FY2010 value amounting to $22328.0.

  • OptimizeRx's Receivables - Other fell 3798.73% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year decrease of 3798.73%. This contributed to the annual value of $3.2 million for FY2024, which is 4666.78% down from last year.
  • As of FY2024, OptimizeRx's Receivables - Other stood at $3.2 million, which was down 4666.78% from $6.1 million recorded in FY2023.
  • In the past 5 years, OptimizeRx's Expense - Property Taxes and Insurance registered a high of $22328.0 during FY2010, and its lowest value of $14054.0 during FY2009.
  • Its 5-year average for Receivables - Other is $3.2 million, with a median of $3.2 million in 2024.
  • Per our database at Business Quant, OptimizeRx's Receivables - Other surged by 17876.58% in 2021 and then plummeted by 4666.78% in 2024.
  • Annual analysis of 5 years shows OptimizeRx's Receivables - Other stood at $757218.0 in 2020, then skyrocketed by 178.77% to $2.1 million in 2021, then skyrocketed by 69.73% to $3.6 million in 2022, then soared by 69.62% to $6.1 million in 2023, then crashed by 46.67% to $3.2 million in 2024.
  • Its Receivables - Other was $3.2 million in FY2024, compared to $6.1 million in FY2023 and $3.6 million in FY2022.